Bergen 19 February 2024 - Reference is made to the stock exchange announcement
on 7 December 2023 regarding the approval and publication of a prospectus
prepared by BerGenBio ASA (the "Company") for the listing of new shares to be
issued by the Company (the "Prospectus").
The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today
approved a prospectus supplement dated 19 February 2024 (the "Prospectus
Supplement") to the Prospectus. The Prospectus Supplement has been prepared
inter alia in connection with the publication by the Company of its results for
the fourth quarter of 2023. The information contained in the Prospectus
Supplement shall be considered an integral part of, and is to be read together
with, the Prospectus. The Prospectus is available, and the Prospectus Supplement
will be made available, on the Company's website:
https://www.bergenbio.com/investors/investor-relations/warrants
For further information, please contact:
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.no
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com
This information is subject to the disclose requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.